Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 29, 2015

View Archived Issues

BGT-1-selective compound SBV-114 has anticonvulsant properties

Theravance Biopharma and Trek Therapeutics begin phase IIa trial of TD-6450

Quark Pharmaceutical begins patient recruitment for global pivotal study of QPI-1007

Amgen and Cytokinetics report topline results from COSMIC-HF

Kite Pharma partners with Alpine Immune Sciences to develop cancer immunotherapies

KaloBios starts phase I trial of KB-003 in patients with CMML

XBiotech to develop oral monoclonal antibody therapy for C. difficile infection

GSK's shingles vaccine containing QS-21 Stimulon shows efficacy against shingles

Ipsen and Telesta sign license agreement for MCNA in Europe and other territories

Cabaletta improves swallowing and muscle strength in phase II trial in OPMD

Absorb heart stent meets primary endpoints in ABSORB III and ABSORB China trials

Bristol-Myers Squibb updates pipeline progress of third quarter 2015

Effects of alemtuzumab in slowing brain volume loss in CARE MS I and II extension study

MVA-BN Filo enhances antibody response to Ebola vaccine candidate

LEO-43204 is effective for treating actinic keratosis on the face and chest

Drosophila cell line-derived Ebola vaccine

Sichuan Haisco Pharmaceutical divulges dual EGFR and HER2 inhibitors

U.S. and Italian team reports development of FAAH inhibitors

Almirall introduces TRPA1 antagonists

NicOx discloses NO donors

University of North Carolina reports MerTK/TYRO3 inhibitors

GSK provides update on LATITUDE-TIMI 60 trial

Gilead submits NDA for fixed-dose combination of sofosbuvir/velpatasvir for HCV

FDA approves Yervoy for adjuvant treatment of fully resected stage III melanoma

World Stroke Day: Neuroprotective microRNA, post-stroke recovery protein identified

LOXO-101 selected for NCI targeted therapy trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...